Search results
Showing 31 to 45 of 534 results for %s
into single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) for treating morbid obesity, particularly research...
and carers bodies representing health professionals manufacturer(s) or sponsor(s) of the technology in development the...
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
are registered stakeholders, including the technology manufacturer(s) or sponsor(s); the diagnostics advisory committee...
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
accompanying assessment and care advice are given to the patient and carer(s). This improves the link between acute and community care,...
Constipation in children and young people: diagnosis and management (CG99)
This guideline covers diagnosing and managing constipation in children and young people up to 18. It provides strategies to support the early identification and timely, effective treatment of constipation which will help improve outcomes for patients. It does not cover constipation caused by a specific condition.
Position statement on use of the EQ-5D-5L value set for England (updated October 2019)
Our position on use of the EQ-5D-5L valuation set for England
This guideline covers diagnosing and managing hypertension (high blood pressure), including pre-eclampsia, during pregnancy, labour and birth. It also includes advice for women with hypertension who wish to conceive and women who have had a pregnancy complicated by hypertension. It aims to improve care during pregnancy, labour and birth for women and their babies.
Evidence summaries: new medicines – Interim process statement (PMG1)
Evidence summaries: new medicines – Interim process statement
This quality standard covers health and social care services for adults, young people and children with autism. It includes assessment and diagnosis of autism spectrum disorders, and care and support for people diagnosed with an autism spectrum disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS51Show all sections
Sections for QS51
- Quality statements
- Quality statement 1: Diagnostic assessment by an autism team
- Quality statement 2: Assessment and diagnosis
- Quality statement 3: Personalised plan
- Quality statement 4: Coordination of care and support
- Quality statement 5: Treating the core features of autism: psychosocial interventions
- Quality statement 6: Treating the core features of autism: medication
- Quality statement 7: Assessing possible triggers for behaviour that challenges
Stakeholder registration: guidelines, quality standards and indicators
Register your organisation to help us develop guidelines, quality standards and indicators
How this decision aid can help 3 Diagram based on original developed by N H S Lothian. Used with permission. Pelvic bone Vagina Urethra...
Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template